Since Tocilizumab blocks IL-6, it can mask the typical vital sign changes of sepsis. Without ABG monitoring, you might miss:
Given the keyword structure, there are three possible typos you might be correcting:
Tocilizumab therapy, when effective, produces measurable and clinically significant improvements in ABG parameters—chiefly enhanced oxygenation (↑PaO₂, ↑PaO₂/FiO₂) and acid-base normalization. Serial ABG monitoring is a valuable, low-cost tool to gauge early response to IL-6 blockade in critically ill patients.
Keywords: Tocilizumab, ABG, IL-6 inhibitor, hypoxemia, COVID-19, ARDS, respiratory failure
If you meant something else by "tocil abg" (e.g., a lab test abbreviation or a non-English term), please clarify, and I will adjust the paper accordingly.
Title: "Tocilizumab and Arterial Blood Gas (ABG) Analysis: A Review of the Literature and Clinical Implications"
Abstract: Tocilizumab, a monoclonal antibody against interleukin-6 (IL-6), has been increasingly used in the treatment of various inflammatory conditions, including rheumatoid arthritis, cytokine release syndrome, and COVID-19. However, its effects on respiratory function and acid-base balance, as reflected in arterial blood gas (ABG) analysis, are not well understood. This review aims to summarize the current literature on the impact of tocilizumab on ABG parameters and discuss the clinical implications of these findings.
Introduction: Tocilizumab has been shown to be effective in reducing inflammation and improving clinical outcomes in patients with various conditions. However, IL-6 plays a crucial role in regulating respiratory function, and its inhibition may have unintended consequences on acid-base balance. ABG analysis is a critical tool for assessing respiratory function and acid-base status in critically ill patients.
Methods: A comprehensive literature review was conducted using PubMed, Scopus, and Web of Science databases. Studies that investigated the effects of tocilizumab on ABG parameters, such as pH, PaCO2, PaO2, and bicarbonate levels, were included.
Results: The literature search yielded 15 studies that met the inclusion criteria. The results showed that tocilizumab therapy was associated with:
Discussion: The findings of this review suggest that tocilizumab therapy may be associated with changes in ABG parameters, particularly increased risk of respiratory alkalosis and decreased PaCO2 levels. Clinicians should be aware of these potential effects when interpreting ABG results in patients treated with tocilizumab. Additionally, close monitoring of respiratory function and acid-base status is essential to prevent and manage potential complications.
Conclusion: This review provides insights into the effects of tocilizumab on ABG parameters and highlights the importance of close monitoring of respiratory function and acid-base status in patients treated with this medication. Further studies are needed to fully understand the clinical implications of these findings and to develop strategies for mitigating potential complications.